Efficacy of Convalescent Plasma Therapy in Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

June 14, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
COVID
Interventions
BIOLOGICAL

Convalescent Plasma

Dose-250 ml Frequency - 2 doses on consecutive days Duration -Start by day 3 of symptom onset (of severe COVID-19 as in inclusion criteria) in eligible patients

OTHER

Standard of Care

The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)

Trial Locations (3)

110006

Maulana Azad Medical College, New Delhi

110070

Institute of Liver & Biliary Sciences, New Delhi

110093

Rajiv Gandhi Super Speciality Hospital, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT04425915 - Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 | Biotech Hunter | Biotech Hunter